Axsome Therapeutics Inc
NASDAQ:AXSM 4:00:00 PM EDT
| Market Cap (Intraday) | 5.07B |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | 63.96 |
| 10-Day MA | $103.58 |
| 50-Day MA | $106.64 |
| 200-Day MA | $102.91 |
Axsome Therapeutics Inc Stock, NASDAQ:AXSM
One World Trade Center, 22nd floor, New York, New York 10007
United States of America
Phone: +1.212.332.3241
Number of Employees: 683
Description
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.